Five Alarm Bio

Executive Summary

Five Alarm Bio is a UK-based biotechnology company founded in 2016 that is pioneering a novel approach to aging by targeting an unexplored mechanism that could delay or prevent multiple age-related diseases. Leveraging well-characterized and inherently safe biology, the company develops small molecule therapeutics aimed at promoting healthier aging. With a research base near Cambridge's Babraham Campus and a sizable workforce of 201-500 employees, Five Alarm Bio has built significant infrastructure despite remaining in the pre-clinical stage. The company's platform is designed to address a broad range of conditions associated with aging, potentially offering a preventative or disease-modifying strategy that could transform geriatric healthcare. While Five Alarm Bio's science is compelling and addresses a large unmet need, the company has not disclosed recent funding rounds or valuation, and no clinical-stage assets have been reported. The pre-clinical phase carries inherent risks, including target validation, preclinical efficacy, and toxicology challenges. However, the size of the employee base suggests substantial investment in research capabilities and possibly a pipeline nearing IND-enabling studies. The company's focus on a novel aging mechanism could attract significant interest from pharma partners and investors, but near-term visibility remains limited pending data releases. Overall, Five Alarm Bio represents an early-stage opportunity with high upside but considerable uncertainty.

Upcoming Catalysts (preview)

• H2 2026Preclinical proof-of-concept data in age-related disease models60% success
• TBDSeries A or B financing round announcement70% success
• 2027IND filing for lead therapeutic candidate40% success